Clinical Liver Disease
© The American Association for the Study of Liver Diseases
Volume 9, Issue 4 Pages 77 - 101, April 2017
Volume 9, Issue 4 Pages 77 - 101, April 2017
Hepatic fibrosis in children and adults
Rebecca G. Wells
Version of Record online: 20 APR 2017 | DOI: 10.1002/cld.623
Watch a video presentation of this article
Just as children are not little adults, pediatric liver fibrosis is not adult fibrosis on a small scale. Although there is some overlap between causes of adult- and pediatric-onset liver diseases, they are for the most part different. Similarly, the susceptibility to injury, best illustrated by BA, can vary markedly by age, in part because of size differences and cell maturity, but also because of factors not yet understood. Finally, the response to injury, including the behavior of fibrogenic and progenitor cells in stimulating matrix deposition, may in many diseases be unique in children. Understanding these differences may be critical to the application of radiological and biomarker diagnostics to pediatric liver disease.
Just as children are not little adults, pediatric liver fibrosis is not adult fibrosis on a small scale. Although there is some overlap between causes of adult- and pediatric-onset liver diseases, they are for the most part different. Similarly, the susceptibility to injury, best illustrated by BA, can vary markedly by age, in part because of size differences and cell maturity, but also because of factors not yet understood. Finally, the response to injury, including the behavior of fibrogenic and progenitor cells in stimulating matrix deposition, may in many diseases be unique in children. Understanding these differences may be critical to the application of radiological and biomarker diagnostics to pediatric liver disease.
Treatment of HCV in persons who inject drugs: Treatment as prevention
Jason Grebely and Gregory J. Dore
Version of Record online: 20 APR 2017 | DOI: 10.1002/cld.626
Watch a video presentation of this article
Watch the interview with the author
Globally, morbidity and mortality caused by hepatitis C virus (HCV) infection continues to grow, particularly among aging cohorts of people who inject drugs (PWID).
Continue reading....
View all articles in the latest issue of Clinical Liver Disease
Globally, morbidity and mortality caused by hepatitis C virus (HCV) infection continues to grow, particularly among aging cohorts of people who inject drugs (PWID).
Continue reading....
View all articles in the latest issue of Clinical Liver Disease
No comments:
Post a Comment